BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

...II testing. They include therapies against ILT4, TIGIT and HIF2A...
...immunoglobulin-like receptor subfamily B member 2HIF2A (HIF-2α; EPAS1...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...targeting next generation immuno-oncology targets, TIGIT and HIF2A. As...
...from the anti-TIGIT mAb vibostolimab and the HIF2a...
...subfamily B member 2HIF2A (HIF-2α; EPAS1) – Endothelial PAS domain protein 1 Lauren...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...in all patients and 8.4 months in PD-L1 expressers. Response rates rise for Merck’s HIF2A inhibitorMerck’s HIF2A...
...candidate in a similar patient population. TARGETSHER3 (ERBB3; EGFR3) – Erb-b2 receptor tyrosine kinase 3 HIF2A (HIF2-α; EPAS1...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

The failure of Akebia’s vadadustat on a Phase III safety endpoint in a subset of chronic kidney disease patients won’t stop the company from submitting the molecule to regulators. But the readout surprised...
BioCentury | Jul 21, 2020
Product Development

Data Bytes: COVID-19 pipeline still growing

Last week saw at least 17 new programs added to the COVID-19 pipeline, bringing the total number of candidates BioCentury is tracking in its COVID-19 Resource Center to 679. Among the 12 new therapeutic entrants...
BioCentury | Jun 30, 2020
Regulation

Data Bytes: Drug approvals in Japan

On Monday, Japan’s Ministry of Health, Labour and Welfare announced at least nine drug approvals, five of which are products from Novartis AG (NYSE:NVS; SIX:NOVN). Two of the approvals are for HIF-PH inhibitors to treat...
BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Inhibiting HIF1A could treat lupus by reducing hypoxia-mediated kidney damage by T cells. In renal biopsies from systemic lupus erythematosus patients, tissue with high T cell infiltration had higher...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

TG’s combo meets Phase III leukemia endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib met the primary endpoint of progression-free survival (PFS) in...
BioCentury | Mar 31, 2020
Product Development

Amarin set to appeal patent ruling that points way to generic competition for Vascepa

Amarin said it will appeal a judge’s patent decision that could blunt the rapid sales growth of cardiovascular drug Vascepa by removing a barrier for generic competition. The ruling, issued after market hours Monday, is...
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

...Merck Phase II programs: ArQule’s BTK inhibitor ARQ 531 for B cell malignancies, and Peloton’s HIF2A...
...for renal cell carcinoma (see “Latest to Jump in Btk Race” ; “Merck Bets on HIF2A”...
...Targets Btk - Bruton’s tyrosine kinase DPP-4 (CD26) - Dipeptidyl peptidase-4 HIF2A (HIF-2α; EPAS1) - Endothelial PAS domain protein 1...
Items per page:
1 - 10 of 714